Back

Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/activated factor XI apple 2 domain

31 August 2024 (13:45 - 13:55)
Organised by: Logo
Congress Presentation Part of: Biotherapies in cardiovascular disease: from bench to bedside Anticoagulants ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Aaron Kithcart

(United States of America)

5 More presentations in this session

Presentation thumbnail
CS585, a novel prostacyclin receptor agonist, demonstrates sustained efficacy in vivo in the prevention of thrombosis
Professor M. Holinstat (Ann Arbor, US)
Abstract Slides Video
Presentation thumbnail
RKER-012, a novel modified ActRIIB ligand trap, attenuated right ventricular cardiomyopathy in a preclinical model of pulmonary arterial hypertension.
Doctor P. Jain (Lexington, US) Doctor K. Babbs (US)
Abstract Slides Video
Presentation thumbnail
First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects
Doctor A. Gabrielsen (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Phase I results of both IV and oral administration for CG-0255: a novel fast-acting antiplatelet drug with a new activation pathway
Doctor X. Chen (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Developing p21-activated kinase 1 (PAK1) activators to treat hypertrophic cardiomyopathy (HCM)
Miss Y. He (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Biotherapies in cardiovascular disease: from bench to bedside
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 13:45 CET
You may be interested in
thumbnail
Congress Presentation
Shaping clinical practice and clinical trials
thumbnail
Congress Presentation
Factor XI inhibition: clinical view on current research and future implications
thumbnail
Congress Presentation
First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources